Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Mediterranean diet cut Parkinson’s risk
MDedge Dermatology
A prescription for medicine’s gender inequality
MDedge Dermatology
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Dermatology
Trump targets abortion by denying family planning funds
MDedge Dermatology
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Dermatology
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Dermatology
Recurrence of Elevated Intracranial Pressure Following Tetracycline Antibiotic Use
MDedge Dermatology
Risk for Appendicitis, Cholecystitis, or Diverticulitis in Patients With Psoriasis
MDedge Dermatology
Patients who want to make you retire, and how to cope
MDedge Dermatology
Erythematous Edematous Plaques on the Dorsal Aspects of the Hands
MDedge Dermatology